Long-Term Efficacy Data for Cosentyx Shows Consistent Skin Clearance in Psoriasis
Patients in the SCULPTURE extension received the same blinded maintenance treatment regimen and dose up to the end of Year 3; the study became open label in Year 4. For patients who were administered Cosentyx 300mg every 4 weeks, almost clear skin (PASI 90) was achieved by 68.5% of patients at Year 1, 61.9% of patients at Year 3, and maintained at Year 4 in 66.4% of patients.
Completely clear skin (PASI 100) was achieved by 43.8% of patients at Year 1, 41.7% of patients at Year 3, and maintained at Year 4 in 43.5% of patients. PASI 75 skin clearance, the historic standard treatment goal, was achieved by 88.9% of patients at Year 1, 78.4% of patients at Year 3, and maintained at 88.5% of patients at Year 4.
In addition, data from the GESTURE study showed that 40% of patients treated with Cosentyx 300mg every 4 weeks achieved clear or almost clear palms and soles at Week 16; at Week 80, about 60% of patients achieved clear or almost clear palms and soles.
Cosentyx is a human monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine. It works by inhibiting its interaction with the IL-17 receptor. In addition to its use in psoriasis, Cosentyx is also indicated for adult patients with active ankylosing spondylitis and active psoriatic arthritis.
For more information call (888) 669-6682 or visit Cosentyx.com.